Chief Executive Offier, Philipp Mathieu, buys Immunovia warrants
LUND, Sweden, Nov. 16, 2022 /PRNewswire/ -- Immunovia AB (NASDAQ: IMMNOV) announces today that Philipp Mathieu, CEO of Immunovia, has purchased 150000 warrants of the 2022/2026 scheme for approximately 297 KSEK.
His total holding now amounts to 2108 shares and 250 000 warrants in Immunovia. The warrants have a subscription price per share of SEK 88.69. Other management team members have subscribed for 100 000 warrants of the same scheme.
For more information, please contact:
Karin Almqvist Liwendahl
CFO
[email protected]
+46 70 911 56 08
About Immunovia
Immunovia AB is a diagnostic company with the vision to revolutionize blood-based diagnostics and increase survival rates for patients with cancer.
Our first product, IMMray™ PanCan-d is the only blood test currently available for early detection of pancreatic cancer. The test has unmatched clinical performance. Commercialization of IMMray™ PanCan-d started in August 2021 in the USA and IMMray™ PanCan-d is offered as a laboratory developed test (LDT) exclusively through Immunovia, Inc. For more information see: www.immunoviainc.com.
Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups globally to make this test available to all high-risk pancreatic cancer groups.
The USA, the first market in which IMMray™ PanCan-d is commercially available, is the world's largest market for the detection of pancreatic cancer with an estimated value of more than USD 4 billion annually.
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com.
The following files are available for download:
Press release (PDF) |
SOURCE Immunovia AB
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article